Trevi Therapeutics, Inc. Gains 23.97%

Mon, Oct 11, 2021 at 05:30 PM
Trevi Therapeutics, Inc. Gains 23.97%

Trevi Therapeutics, Inc. (TRVI:NASDAQ) jumped higher at $1.5, representing a gain of 24%. On Fri, Oct 08, 2021, TRVI:NASDAQ hit a New 2-Week Low of $1.2. The stock appeared on our News Catalysts scanner on Thu, Oct 07, 2021 at 05:07 PM in the 'BIOTECH' category. From Fri, Sep 24, 2021, the stock recorded 30.00% Up Days and 36.36% Green Days

About Trevi Therapeutics, Inc. (TRVI:NASDAQ)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.

Get 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
Your price will remain at $9.99 USD after the discount period
$9.99 USD
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... or other trends? You're in the right place! Check StockTreats features.